The short version of research compound fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
In contrast to rheumatoid arthritis, in osteoarthritis the joints do not become hot or red. Treatment includes exercise, decreasing joint stress such as by rest or use of a cane, support groups, and pain medications. Weight loss may help in those who are overweight. Pain medications may include paracetamol (acetaminophen) as well as NSAIDs such as naproxen or ibuprofen. Long-term opioid use is not recommended due to lack of information on benefits as well as risks of addiction and other side effects. Joint replacement surgery may be an option if there is ongoing disability despite other treatments. More than 90% of hip and knee joint replacements are due to osteoarthritis. An artificial hip or knee joint typically lasts more than 20 years. Osteoarthritis is the most common form of arthritis, affecting about 237 million people or 3.3% of the world's population as of 2015. It becomes more common as people age. Among those over 60 years old, about 10% of males and 18% of females are affected. Osteoarthritis is the cause of about 2% of years lived with disability. Those with osteoarthritis of the hips or knees (the most commonly affected large joints) have a 20% increased risk of mortality, possibly due to reduced activity levels.
=== United States === Pizza Hut's first television commercial was produced in 1965 by Bob Walterscheidt for the Harry Crow agency in Wichita, and was entitled "Putt-Putt to the Pizza Hut". The ad looks just like an old movie and is set in fast motion. It features a man in a business suit and tie, played by Ron Williams, who was then a production manager for Wichita's ABC affiliate KAKE-TV, as he orders take-out, leaves his house, and gets into his 1965 Mustang JR to drive to Pizza Hut, where he is chased by a variety of townspeople, portrayed by neighborhood kids, Walterscheidt and his daughter, and various employees for Harry Crow and KAKE-TV. He goes inside Pizza Hut to pick up his pizza and drives home. People eat all the pizza before the man who ordered it can get any, which makes the man very upset, so he calls Pizza Hut again. The ad first aired on November 19, 1966, during halftime of the Notre Dame vs. Michigan State "Game of the Century", and dramatically increased sales for the franchise. "Putt-Putt to the Pizza Hut" ran on TV for eight years and was nominated for a Clio Award. Until early 2007, Pizza Hut's main advertising slogan was "Gather 'round the good stuff". From 2008 to 2009, the advertising slogan was "Now You're Eating!" From 2009 to 2012, the advertising slogan was "Your Favorites. Your Pizza Hut" From 2012 to 2016, the advertising slogan was "Make it great", a variation of the 1987–1995 slogan "Makin' it great!". From 1995 to 1999, the slogan was "You'll love the stuff we're made of". The advertising slogan is currently "No one outpizzas the hut".
== Chemical structure and properties == ECG is a flavonoid with a molecular formula of C22H18O10 and a molecular weight of 442.4 g/mol. Its structure comprises a flavan-3-ol backbone (epicatechin) esterified with gallic acid at the 3-position, featuring two catechol rings and a trihydroxybenzoate ring with multiple hydroxyl groups. In test tube experiments, the galloyl moiety enhances ECG's radical scavenging compared to epicatechin, with a DPPH assay showing higher antioxidant activity due to the additional hydroxyl groups. ECG is soluble in water, ethanol, and dimethyl sulfoxide, but degrades significantly in boiling water, limiting its stability in tea preparation.
Sources: en.wikipedia.org
=== Civic Society === Bromley Civic Society is a civic society for the historic centre of Bromley. It is a founder member of Civic Voice. It seeks to educate the public about the community's history and to preserve historical sites.
== Discovery == German chemist Felix Ehrlich discovered isoleucine while studying the composition of beet-sugar molasses 1903. In 1907 Ehrlich carried out further studies on fibrin, egg albumin, gluten, and beef muscle in 1907. These studies verified the natural composition of isoleucine. Ehrlich published his own synthesis of isoleucine in 1908.
The 1970s saw a shift in audience tastes to high concept films, with five such films made by either George Lucas or Steven Spielberg topping the chart during the 1980s. The 21st century has seen an increasing dependence on franchises and adaptations, with the box-office dominance of films based on pre-existing intellectual property at record levels. Steven Spielberg (1975, 1981, 1982, 1989 and 1993) and Cecil B. DeMille (1932, 1947, 1949, 1952 and 1956) tie as the most represented directors on the chart with five films apiece occupying the annual top spot. William Wyler (1942, 1946, 1959 and 1968) and James Cameron (1991, 1997, 2009 and 2022) are each represented by four films, whilst D. W. Griffith (1915, 1916 and 1920), George Roy Hill (1966, 1969 and 1973) and the Russo brothers (2016, 2018 and 2019) all feature heavily with three films apiece. George Lucas directed three chart-toppers in 1977, 1999 and 2005, but also served in a strong creative capacity as a producer and writer in 1980, 1981, 1983, and 1989 as well. The following directors have also all directed two films on the chart: Frank Lloyd, King Vidor, Frank Capra, Michael Curtiz, Leo McCarey, Alfred Hitchcock, David Lean, Stanley Kubrick, Guy Hamilton, Mike Nichols, William Friedkin, Peter Jackson, Gore Verbinski, and Michael Bay; Mervyn LeRoy, Ken Annakin and Robert Wise are each represented by one solo credit and one shared credit, and John Ford co-directed two films.
Sources: en.wikipedia.org
The Colombian conflict (Spanish: Conflicto armado interno de Colombia, lit. 'Colombian internal armed conflict') began on May 27, 1964, and is a low-intensity asymmetric war between the government of Colombia, paramilitary groups, crime syndicates, and far-left guerrilla groups engaged in armed factional hostilities to increase their influence in Colombian territory. Some of the most important international contributors to the Colombian conflict include multinational corporations, the United States, Cuba, and the drug trafficking industry. The conflict is historically rooted in the conflict known as La Violencia, which was triggered by the 1948 assassination of liberal political leader Jorge Eliécer Gaitán and in the aftermath of the anti-communist repression in rural Colombia in the 1960s that led Liberal and Communist militants to re-organize into the Revolutionary Armed Forces of Colombia (FARC). The reasons for fighting vary from group to group. The FARC and other guerrilla movements claim to be fighting for the rights of the impoverished in Colombia to protect them from government violence and to provide social justice through communism. The Colombian government claims to be fighting for order and stability, and to protect the rights and interests of its citizens. The paramilitary groups claim to be reacting to perceived threats by guerrilla movements.
== Equipment == Special medical equipment may be used, such as fiber optic cables, miniature video cameras and special surgical instruments handled via tubes inserted into the body through small openings in its surface. The images of the interior of the body are transmitted to an external video monitor and the surgeon has the possibility of making a diagnosis, visually identifying internal features and acting surgically on them.
=== Adverse effects === The most common adverse effects of medicinal nicotinic acid (500–3000 mg) are flushing (e.g., warmth, redness, itching or tingling) of the face, neck and chest, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rhinitis, pruritus and rash. These can be minimized by initiating therapy at low dosages, increasing dosage gradually, and avoiding administration on an empty stomach. The acute adverse effects of high-dose nicotinic acid therapy (1–3 grams per day) – which is commonly used in the treatment of hyperlipidemias – can further include hypotension, fatigue, glucose intolerance and insulin resistance, heartburn, blurred or impaired vision, and macular edema. With long-term use, the adverse effects of high-dose nicotinic acid therapy (750 mg per day) also include liver failure (associated with fatigue, nausea, and loss of appetite), hepatitis, and acute liver failure; these hepatotoxic effects of nicotinic acid occur more often when extended-release dosage forms are used. The long-term use of nicotinic acid at greater than or equal to 2 grams per day also significantly increases the risk of cerebral hemorrhage, ischemic stroke, gastrointestinal ulceration and bleeding, diabetes, dyspepsia, and diarrhea.
== Procedure == Typically, the ammonium sulfate concentration is increased stepwise, and the precipitated protein is recovered at each stage. This is usually done by adding solid ammonium sulfate; however, calculating the amount of ammonium sulfate that should be added to add to a solution to achieve the desired concentration may be difficult because the addition of ammonium sulfate significantly increases the volume of the solution. The amount of ammonium sulfate that should be added to the solution can be determined from published nomograms or by using an online calculator. The direct addition of solid ammonium sulfate does change the pH of the solution, which can lead to loss of enzyme activity. In those cases, the addition of saturated ammonium sulfate in a suitable buffer is used as an alternative to adding solid ammonium sulfate. In either approach, the resulting protein precipitate can be dissolved individually in a standard buffer and assayed to determine the total protein content. The ammonium sulfate concentration added should be increased to a value that will precipitate most of the protein of interest whilst leaving the maximum amount of protein contaminants still in the solution. The precipitated protein of interest can subsequently be recovered by centrifugation and dissolved in standard buffer to prepare the sample for the next stage of purification. In the next stage of purification, all this added salt needs to be removed from the protein. One way to do so is using dialysis, but dialysis further dilutes the concentrated protein.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.